These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

444 related articles for article (PubMed ID: 28111042)

  • 61. Silencing PD-1 and PD-L1: the potential of PolyPurine Reverse Hoogsteen hairpins for the elimination of tumor cells.
    Ciudad CJ; Medina Enriquez MM; Félix AJ; Bener G; Noé V
    Immunotherapy; 2019 Apr; 11(5):369-372. PubMed ID: 30786843
    [No Abstract]   [Full Text] [Related]  

  • 62. Blocking immune checkpoints in prostate, kidney, and urothelial cancer: An overview.
    Alme AK; Karir BS; Faltas BM; Drake CG
    Urol Oncol; 2016 Apr; 34(4):171-81. PubMed ID: 26923782
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The efficacy and safety of anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory cancers: a meta-analysis.
    Zhang T; Xie J; Arai S; Wang L; Shi X; Shi N; Ma F; Chen S; Huang L; Yang L; Ma W; Zhang B; Han W; Xia J; Chen H; Zhang Y
    Oncotarget; 2016 Nov; 7(45):73068-73079. PubMed ID: 27683031
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Building on the anti-PD1/PD-L1 backbone: combination immunotherapy for cancer.
    Ingles Garces AH; Au L; Mason R; Thomas J; Larkin J
    Expert Opin Investig Drugs; 2019 Aug; 28(8):695-708. PubMed ID: 31359805
    [No Abstract]   [Full Text] [Related]  

  • 65. The use of immunotherapy in the treatment of melanoma.
    Achkar T; Tarhini AA
    J Hematol Oncol; 2017 Apr; 10(1):88. PubMed ID: 28434398
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Immunotherapy in genitourinary cancers: achievements and perspectives.
    Xylinas E; Roumiguié M; Sargos P
    World J Urol; 2021 May; 39(5):1317. PubMed ID: 34003335
    [No Abstract]   [Full Text] [Related]  

  • 67. Hyperprogressive disease with anti-PD-1 and anti-PD-L1.
    Brower V
    Lancet Oncol; 2016 Dec; 17(12):e527. PubMed ID: 27866860
    [No Abstract]   [Full Text] [Related]  

  • 68. Chemotherapy of uroepithelial tumors.
    Goldstein G
    Prog Clin Biol Res; 1978; 25():105-15. PubMed ID: 366625
    [No Abstract]   [Full Text] [Related]  

  • 69. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
    Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
    Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Immunotherapy in Urothelial Cancer: Recent Results and Future Perspectives.
    Farina MS; Lundgren KT; Bellmunt J
    Drugs; 2017 Jul; 77(10):1077-1089. PubMed ID: 28493171
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Carcinoembryonic antigen in patients with urologic cancers.
    Guinan P; Ablin RJ; Barakat H; John T; Sadoughi N; Bush IM
    Urol Res; 1973 Oct; 1(3):101-5. PubMed ID: 4804082
    [No Abstract]   [Full Text] [Related]  

  • 72. Understanding and overcoming resistance to immunotherapy in genitourinary cancers.
    Evans ST; Jani Y; Jansen CS; Yildirim A; Kalemoglu E; Bilen MA
    Cancer Biol Ther; 2024 Dec; 25(1):2342599. PubMed ID: 38629578
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Which checkpoint inhibitor? An embarrassment of riches for bladder cancer.
    Gill DM; Sonpavde G; Pal SK; Agarwal N
    Immunotherapy; 2017 May; 9(6):463-466. PubMed ID: 28472906
    [No Abstract]   [Full Text] [Related]  

  • 74. Biomarkers for immunotherapy in urological cancers.
    Gust KM; Resch I; D'Andrea D
    Curr Opin Urol; 2018 Jan; 28(1):25-28. PubMed ID: 29120910
    [TBL] [Abstract][Full Text] [Related]  

  • 75. PD-L1 and immune escape: insights from melanoma and other lineage-unrelated malignancies.
    Frydenlund N; Mahalingam M
    Hum Pathol; 2017 Aug; 66():13-33. PubMed ID: 28694003
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Immune-checkpoint inhibitors and metastatic prostate cancer therapy: Learning by making mistakes.
    Claps M; Mennitto A; Guadalupi V; Sepe P; Stellato M; Zattarin E; Gillessen SS; Sternberg CN; Berruti A; De Braud FGM; Verzoni E; Procopio G
    Cancer Treat Rev; 2020 Aug; 88():102057. PubMed ID: 32574991
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Immunology of genitourinary tumors.
    Guinan P; Sadoughi N; Bush IM; John T; Eghrari F; Ablin RJ
    Urology; 1973 Nov; 2(5):493-9. PubMed ID: 4131868
    [No Abstract]   [Full Text] [Related]  

  • 78. Perspectives on the clinical development of immunotherapy in prostate cancer.
    Cordes LM; Gulley JL; Madan RA
    Asian J Androl; 2018; 20(3):253-259. PubMed ID: 29582792
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Immune checkpoint inhibitors for metastatic bladder cancer.
    Massari F; Di Nunno V; Cubelli M; Santoni M; Fiorentino M; Montironi R; Cheng L; Lopez-Beltran A; Battelli N; Ardizzoni A
    Cancer Treat Rev; 2018 Mar; 64():11-20. PubMed ID: 29407369
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Is This Patient With Metastatic Bladder Cancer a Candidate for Second-Line Immunotherapy Treatment?
    Bourlon MT; Velázquez HE; Luna-Santiago R; Vázquez-Manjarrez S; Bourlon C
    Oncology (Williston Park); 2018 Feb; 32(2):64-8. PubMed ID: 29492946
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.